What Инфулган Treats: Main Uses and Benefits

The medication is used in situations involving certain distressing symptoms, focusing on two key domains of patient distress. It is generally applied when short-term symptomatic assistance is needed.

Easing Acute Discomfort and Fever

Инфулган is commonly used to help manage symptoms related to physical discomfort and is applied in addressing systemic hyperthermia (fever). It is relevant for easing mild-to-moderate pain and may be part of symptomatic management for more pronounced discomfort when used with stronger painkillers. The medication is typically applied in clinical settings that involve acute or unstable symptom patterns, such as during postoperative care, or when non-oral administration is relevant. By addressing these symptom clusters, it contributes to easing the overall symptom load and helps patients cope more steadily with difficult episodes.

“This medication is considered relevant for managing symptoms that interfere with daily comfort, especially in urgent care scenarios.”

Quick Fact: Symptomatic Support The medication is relevant for acute pain and high fever, and may assist with managing symptoms when additional support is needed in comprehensive treatment plans.

The eligibility profile for Инфулган (intravenous paracetamol) is strictly governed by patient-specific factors, particularly weight and pre-existing organ function, as defined in official regulatory labeling.

Absolute Contraindications

Use of the medicine must not occur if the patient meets the following criteria:

• Hypersensitivity: Known allergy to paracetamol, its prodrug (propacetamol), or any excipients.
• Severe Liver Disease: Patients with severe hepatocellular insufficiency or decompensated active liver disease.

Eligibility Across Age Groups

Age Group	Official Regulatory Status	Classification
Term Newborns & Infants	Use is allowed; dose volume is strictly based on weight (le 10 kg) and requires specialized vials.	Conditional Use
Children & Adults	Use is allowed; dose volume is determined by weight. Adults over 50 kg typically receive a standard dose.	Allowed
Premature Newborns	Not recommended due to a lack of established safety and efficacy data.	Use Not Established

Conditional Use and Restrictions

Use of the medicine requires caution and potential dose adjustment in populations with high risk for liver injury or accumulation:

• Severe Renal Impairment: Patients with creatinine clearance le 30 mL/min require the minimum dosing interval to be extended to at least 6 hours.
• Risk of Glutathione Depletion: Caution is advised in individuals with chronic alcoholism, chronic malnutrition, or dehydration, often requiring a reduction in the maximum daily dose.
• Pregnancy and Lactation: Use is permitted if clinically necessary during pregnancy, provided the lowest effective dose is utilized for the shortest duration. The medicine is generally allowed during breastfeeding.

Interactions with other medicines and products

Regulatory documentation outlines specific interaction patterns for Инфулган, whose active ingredient is Paracetamol (Acetaminophen), focusing on changes to drug exposure and pharmacodynamic effects.

---

Official Interaction Statements

• Exposure-Modifying Agents: Co-administration with Probenecid is officially documented to inhibit paracetamol conjugation, reducing its clearance and resulting in a substantial increase in systemic exposure ( AUC). Conversely, strong enzyme inducers like Phenobarbital or Rifampicin officially increase paracetamol’s metabolic clearance, potentially leading to lower drug levels and a heightened risk of hepatotoxicity.
• Enhanced Anticoagulation: The co-administration of paracetamol with Oral Anticoagulants (e.g., Warfarin and coumarin derivatives) has been documented to cause a pharmacodynamic potentiation that may lead to an increase in the INR and risk of bleeding, particularly when high doses are used for prolonged periods.
• Specific Drug Combinations: Co-administration with Zidovudine (AZT) is officially associated with an increased risk of neutropenia.
• Non-Medicinal Substances: Chronic Excessive Alcohol Intake is documented to increase the official risk of severe paracetamol-related liver damage.

---

Interaction-Related Constraints

• Timing Separation: The administration of Colestyramine should be separated by at least one hour to avoid a documented reduction in paracetamol absorption.
• Population Cautions: The severity of metabolic interactions and the associated risk of hepatotoxicity are officially noted as being higher in patients with pre-existing Severe Hepatic Impairment or chronic alcoholism.

Central Enzyme Inhibition and Thermoregulation

The active ingredient primarily engages in a peroxide-sensitive inhibition of Cyclooxygenase (COX) enzyme function located within the central nervous system (CNS), specifically limiting the synthesis of Prostaglandin E2 in the hypothalamus. This molecular action contributes to the correction of the elevated hypothalamic set point, initiating the physiological processes (like vasodilation) that influence the body's thermoregulatory response.

Dual-Pathway Central Pain Modulation

The nociceptive mechanism is complex, involving the potentiation of the descending inhibitory serotonergic pathway alongside the activity of a metabolite that modulates the TRPV1 and CB1 receptors in the brain and spinal cord. These parallel actions attenuate the transmission and amplification of nociceptive signals, thereby modulating central nociceptive processing.

Onset Dynamics via Rapid Target Engagement

The intravenous formulation facilitates the immediate, high-concentration delivery of the active substance, ensuring rapid passage across the blood-brain barrier and swift access to its central enzymatic and receptor targets. This accelerated target engagement is linked to the rapid initiation of pathway modulation in the CNS.

How Инфулган is Used: Official Administration Guidelines

Инфулган is a formulation of paracetamol that is governed by specific instructions concerning its administration route, dosage, and timing.

---

Administration Scope and Procedure

Property	Official Use Instruction
Route of Administration	Exclusively via intravenous (IV) infusion.
Administration Time	The infusion must be administered slowly over a period of 15 minutes.
Preparation Requirements	The solution is for single use. It may be administered directly or diluted, but use of the prepared solution must commence within 1 hour of first opening the container.

---

Official Dosing and Frequency

All dosing for Инфулган is strictly based on the patient's body weight and must adhere to specific time intervals to prevent accumulation.

• Standard Adult Dosing (50 kg): The typical single dose is 1000 mg per administration. The maximum total daily dose from all paracetamol sources (IV, oral, etc.) must not exceed 4000 mg (4 g) over 24 hours.
• Dosing Interval: A minimum interval of 4 hours is mandated between sequential administrations for patients without risk factors.
• Population Adjustments: For patients with severe renal impairment (Creatinine Clearance < 30 mL/min), the official instruction is to extend the minimum interval between doses to 6 hours.
• Pediatric and Low-Weight Adult Dosing: Doses for all patients weighing less than 50 kg are determined based on 15 mg/kg per administration, with different maximum limits applying to lower weight categories.

This medication is officially designated for short-term treatment in a controlled clinical environment, and patients are typically transitioned to oral paracetamol as soon as possible.

Research Overview

Инфулган is the intravenous (IV) form of paracetamol (acetaminophen), with research focusing on acute hospital settings. The evidence base is primarily composed of Randomized Controlled Trials (RCTs) and high-level Meta-analyses that describe patterns observed in specific, short-term scenarios.

---

Primary Areas of Study

Clinical evaluation has concentrated on three main outcomes. Research examined the use of IV paracetamol for outcomes related to physical discomfort following surgery, monitoring changes in patient-reported pain scores and the quantity of subsequent analgesic medication. Studies also explored contexts involving systemic hyperthermia (fever), where controlled trials reported measurements related to changes in body temperature observed during the study period. A secondary application studied was the association with preventing involuntary shivering (tremors) in patients recovering from anesthesia. For all primary uses, the follow-up durations were typically limited to the first 24 hours post-procedure.

---

Populations, Long-Term Gaps, and Limitations

Research has focused extensively on both adults and pediatric patients within acute care. The results apply only to the populations studied, and evidence quality varies across these specific groups. A major limitation across the evidence base is the restricted duration of follow-up; there is limited information for long-term outcomes or durability of effect related to chronic management. Furthermore, when combining study results, findings were mixed in some analyses due to high variability across different surgical types, and comparative evidence is lacking for some alternative treatments.

Key Studies & References

1. WHO Model List of Essential Medicines

Common questions about Инфулган (FAQ)

---

Q: Какие побочные эффекты Инфулгана самые частые?

A: According to official regulatory documents, common side effects are those that may affect between 1 in 100 and 1 in 10 patients. These commonly documented reactions, listed in official information, may include nausea, vomiting, insomnia, and headache. The possibility of serious side effects, such as acute liver failure, is noted in regulatory warnings, especially when the maximum recommended dose is exceeded.

---

Q: Через сколько дней обычно проходит температура, если пить Инфулган?

A: As an intravenous formulation, Инфулган is designed to provide rapid relief. The fever-reducing (antipyretic) effect typically begins within 30 minutes of administration. The duration of the fever-reducing effect is typically at least six hours, aligning with the minimum interval between administrations.

---

Q: С чем нельзя совмещать Инфулган (какие лекарства или продукты)?

A: Official documentation lists specific drugs with known interaction patterns. These include Probenecid, certain oral anticoagulants (like Warfarin), and Zidovudine. Furthermore, chronic excessive alcohol consumption is known to increase the risk of serious liver damage related to paracetamol.

---

Q: Можно ли принимать Инфулган одновременно с парацетамолом или ибупрофеном?

A: Regulatory guidelines emphasize the importance of not exceeding the maximum total daily dose of paracetamol, and this limit includes paracetamol received from all sources (IV, oral, etc.). While the combination with other pain relievers, such as Ibuprofen, is not prohibited by official labeling, co-administration with other pain relievers must be carefully managed by a healthcare provider.

---

Q: Как долго можно принимать Инфулган без перерыва?

A: Инфулган is officially designated for short-term use in a controlled clinical environment. The maximum recommended duration for treatment typically does not exceed 72 hours (3 days).

---

Q: Можно ли давать Инфулган детям и с какого возраста?

A: Official guidelines state that the use of Инфулган is allowed in children. Administration is generally permitted for children weighing more than 10 kg and aged over 1 year, though some regional guidelines permit use from 3 months of age. Dosage is strictly determined by the patient's weight.

---

Q: Есть ли разные формы выпуска у Инфулгана (таблетки, капсулы, сироп)?

A: Инфулган is strictly a pharmaceutical preparation supplied as a solution for intravenous infusion (IV drip). It is only available as a liquid solution for injection into a vein, and no other forms, such as tablets, capsules, or syrups, exist under this brand name.

---

Q: Есть ли ограничения по приему Инфулгана для водителей?

A: According to official product documentation, Инфулган is not expected to affect a patient's ability to drive or operate machinery. However, patients should monitor for any adverse reactions, which could potentially impair abilities.

---

Q: Какая максимальная продолжительность лечения Инфулганом?

A: The treatment is intended for short-term use in acute settings. The maximum duration of treatment usually does not exceed 72 hours (3 days), with limits on the number of infusions permitted within a 24-hour period.

---

Q: Инфулган вызывает сонливость?

A: Official regulatory lists of common side effects do not include drowsiness (sleepiness). However, other central nervous system effects, such as insomnia (inability to sleep) or anxiety, have been documented.

---

Q: Нужно ли принимать Инфулган с едой или натощак?

A: Since Инфулган is administered exclusively through intravenous infusion directly into a vein, its use is not dependent on whether the patient has eaten or is fasting.

---

Q: Может ли Инфулган влиять на результаты анализов?

A: Yes, official warnings note that paracetamol, the active ingredient, can potentially interfere with certain laboratory tests if present in high concentrations. This typically relates to tests for uric acid and blood glucose levels.

---

Q: Может ли Инфулган быть опасен для людей с астмой?

A: While regulatory documents do not list asthma as a specific contraindication, they strictly prohibit use in patients with a known allergy or hypersensitivity to paracetamol or any of the product's components. Use requires caution in patients with hypersensitivity issues, and the treatment plan is managed by the treating clinician.

---

Q: Есть ли в составе Инфулгана сахар или лактоза?

A: Инфулган is an aqueous solution for infusion. Official product documents do not list sugar or lactose as components, but it does contain other excipients, such as sodium.

The storage and disposal instructions for Инфулган (Propacetamol solution for infusion) adhere strictly to official regulatory requirements to ensure product integrity.

Storage Conditions

• Unopened Vials: Store the medicinal product below 25°C (77°F). The product must be kept in its original outer carton to protect it from light.
• Child Safety: All medicine must be kept out of the sight and reach of children.

Stability After Preparation

• Post-Dilution Shelf-Life: After reconstitution or dilution, the solution is chemically and physically stable for a maximum of 24 hours when stored in a refrigerated environment between 2°C and 8°C (36°F and 46°F).

Disposal Requirements

• Procedures: Unused or expired Инфулган and waste materials must be disposed of in accordance with local requirements for pharmaceutical waste.
• Prohibition: The medicine must not be disposed of via household waste or wastewater.